Ceapro Inc V.CZO

Chemicals Specialty Chemicals

Ceapro Inc. is a Canada-based biotechnology company. The Company is involved in the development of extraction technology and the application of this technology to the production of extracts and active ingredients from oats and other renewable plant resources. Its primary business activities relate to the development and commercialization of natural products for personal care, cosmetic, human, and animal health industries using technology, natural, renewable resources, and developing products, technologies, and delivery systems. The Company's products include a commercial line of natural active ingredients, including beta glucan, avenanthramides (colloidal oat extract), oat powder, oat oil, oat peptides, and lupin peptides, a commercial line of natural anti-aging skincare products, utilizing active ingredients, including beta glucan and avenanthramides and veterinary therapeutic products, including an oat shampoo, an ear cleanser, and a dermal complex/conditioner.

TSXV:CZO - Post by User

Ceapro Inc > Is that our way?

<< Previous

Bullboard Posts

Next >>

Comment by prophetoffactzon Jan 16, 2024 8:49am

56 Views

Post# 35828571

RE:Is that our way?

Why would that be CZO's way? You posted that CZO has a path to quickly triple sales to over $50 million with PGX. PGX has essentially advanced as expected since with 50L commissioning expected in the next two months and 100L commissioning expected in Q4. Now Gilles may have found an incredible way to secure the capital required for PGX expansion effectively at $1.25 per CZO share with no warrants given HC Wainwrights US$15 AEZS target price(C$100 million market cap) and that it is a merger of equals. When you posted about CZO quickly tripling sales not in your fondest dreams did you mention being able to raise money at C$1.25 per share. Gilles has bestest your fondest dreams. The 100L facility takes CZO to the point of mass commercialization.

fossi_2002 wrote: https://de.advfn.com/borse/NASDAQ/RNAZ/chart/streaming

TransCode Therapeutics Announces 1-for-40 Reverse Stock Split

TransCode Therapeutics Reports Further Restructuring to Reduce Expenses and Increased Focus on Planned Phase 1 Clinical Trial, Retirement of CEO

The chart is similar to that of Aeterna.
If the rest comes in the same way - good night dear Ceapro shareholders. The CEO's ritirement will then be too late for us. Gilles should clear the way for a committed new CEO.